Immunogenic Cell Death and Associated Antitumor Immunity: 2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 April 2025
Special Issue Editor
Interests: nanoparticles; cancer; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues, Roughly 20 years ago, studies by Zitvogel, Kroemer, and their colleagues showed that some commonly used cytotoxic cancer drugs were stimulating antitumor immune responses against tumors, which were important in those drugs’ treatment efficacy. This generated the concept of “immunogenic cell death” (ICD) and added “death-associated molecular patterns” (DAMPS) as additional immunogenic signals to “pathogen-associated molecular patterns” (PAMPS). It also most importantly caused oncologists to realize that in fact, antitumor immune response had been part of their clinical practice and as a result, while it had previously been ignored and thought to be unimportant by many oncologists, it was finally taken seriously. By 2010, the concept that antitumor immunity was valid and important in cancer biology was established (after over 100 years of debate), and soon after, the first T cell checkpoint blocking antibodies were clinically approved. How ICD, caused by cytotoxic chemotherapy or other cancer treatments such as radiation or heat, interacts with the immune system is still an important topic of active research. This Special Issue is designed to assemble important work in the area of ICD due to cancer therapy, how it interacts with natural or treatment-generated antitumor immunity, and how that response can be further strengthened to improve outcomes for patients
Prof. Dr. Steven Fiering
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunogenic cell death
- antitumor immunity
- abscopal effect
- cancer biology
- cancer therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
